Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults.
Ackerson B, Tseng HF, Sy LS, Solano Z, Slezak J, Luo Y, Fischetti CA, Shinde V. · 2019
Read Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults. by Ackerson B, Tseng HF, Sy LS, Solano Z, Slezak J, Luo Y, Fischetti CA, Shinde V. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6603263.txt.
Introduction
Ackerson and co-authors compare two winter viruses in hospitalized older adults. Their study appears in Clinical Infectious Diseases. Respiratory syncytial virus, or RSV, is well known in small children. Its burden in older adults is often overlooked. The team set RSV beside influenza, a familiar yardstick.
The authors drew records from Kaiser Permanente Southern California. They found 645 RSV cases and 1,878 influenza cases from 2011 to 2015. All patients were aged 60 or older. RSV patients were slightly older and had more heart failure and lung disease. After adjustment, RSV carried higher odds of pneumonia and long stays. It also raised one-year mortality odds. The authors urge wider recognition as RSV vaccines near use.
Catalog record
| CREATOR | Ackerson B, Tseng HF, Sy LS, Solano Z, Slezak J, Luo Y, Fischetti CA, Shinde V. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults By Bradley Ackerson, Hung Fu Tseng, Lina S Sy, Zendi Solano, Jeff Slezak, Yi Luo, Christine A Fischetti, Vivek Shinde Published in: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America DOI: 10.1093/cid/ciy991 ABSTRACT Abstract Background Respiratory syncytial virus (RSV) is an important cause of serious respiratory illness in older adults. Comparison of RSV and influenza infection in hospitalized older adults may increase awareness of adult RSV disease burden. Methods Hospitalized adults aged ≥60 years who tested positive for RSV or influenza between 1 January 2011 and 30 June 2015 were identified from Kaiser Permanente Southern California electronic medical records. Baseline characteristics, comorbidities, utilization, and outcomes were compared. Results The study included 645 RSV- and 1878 influenza-infected hospitalized adults. Patients with RSV were older than those with influenza (mean, 78.5 vs 77.4 years; P = .035) and more likely to have congestive heart failure (35.3% vs 24.5%; P < .001) and chronic obstructive pulmonary disease (COPD) (29.8% vs 24.3%; P = .006) at baseline. In adjusted analyses, RSV infection was associated with greater odds of length of stay ≥7 days (odds ratio [OR] = 1.5; 95% confidence interval [CI], 1.2–1.8; P < .001); pneumonia (OR = 2.7; 95% CI, 2.2–3.2; P < .001); intensive care unit admission (OR = 1.3; 95% CI, 1.0–1.7; P = .023); exacerbation of COPD (OR = 1.7; 95% CI, 1.3–2.4; P = .001); and greater mortality within 1 year of admission (OR = 1.3; 95% CI, 1.0–1.6; P = .019). Conclusions RSV infection may result in greater morbidity and mortality among older hospitalized adults than influenza. Increased recognition of adult RSV disease burden will be important in the evaluation and use of new RSV vaccines and antivirals. Keywords: respiratory syncytial virus, influenza, adult, hospitalization, mortality (See the Editorial Commentary by Branche on pages 204–6.) Respiratory syncytial virus (RSV) initially was found to be a common cause of severe respiratory illness in young children [1, 2]. While mild disease in healthy young adults has also been described [3], the potential for RSV to cause severe disease in adults was not recognized until reports of outbreaks among older adults residing in long-term care facilities emerged [4, 5]. Subsequently, RSV was shown to cause serious illness among healthy, community-dwelling older adults. A landmark study of high-risk and community-dwelling adults aged ≥65 years and high-risk adults in the United States detected RSV infection in 3%–7% of healthy, community-dwelling older adults, 4%–10% of high-risk adults, and 16% of adults hospitalized with cardiopulmonary infections [6]. Furthermore, RSV infection was estimated to result in approximately 177000 hospitalizations, 10000 to 14000 deaths, and more than $1 billion dollars in healthcare costs per year in the United States, mostly among older adults [6, 7]. Nonetheless, RSV remains clinically underrecognized by most healthcare providers as a cause of severe respiratory disease in adults [7–9]. A current comparison of the clinical characteristics and burden of RSV illness with those of influenza, a well-recognized cause of severe morbidity and mortality in older adults [10], may increase provider awareness of the potential of RSV infection to cause severe lower respiratory tract disease in older adults. Appreciation of the potential for RSV infection to cause serious illness similar to that caused by influenza will likely trigger more testing for RSV in addition to testing for influenza and direct therapy to the identified etiology in patients as newer agents become available. In addition, recent data on the epidemiology and clinical outcomes of older adults hospitalized with RSV are critical to the evaluation of more than 50 RSV vaccines, monoclonal antibodies, and antivirals currently under development prior to their introduction [11]. While a number of important studies have described the burden and clinical characteristics of RSV and influenza disease in hospitalized older adults, most of these studies were conducted at least a decade ago [6, 12–15]. Furthermore, long-term mortality has not been analyzed previously. Therefore, we evaluated a large cohort of adults aged ≥60 years hospitalized with RSV or influenza A/B infection during 5 consecutive seasons. Demographics, prehospitalization characteristics, hospital utilization, and clinical outcomes, including long-term mortality, were assessed and compared between adults with RSV infection and those with influenza virus infection. METHODS Setting This observational, retrospective, cohort study was conducted at Kaiser Permanente Southern California (KPSC), an integrated healthcare system that provides comprehensive prepaid health services for 4.4 million members cared for at 15 large, community-based hospitals that are owned and operated by KPSC. The demographic makeup of the KPSC membership closely mirrors the racially and sociodemographically diverse Southern California population and the California census population; more than 99% are community dwelling [16]. As KPSC is a prepaid healthcare system, there is a very strong motivation for members to use services internally. Furthermore, reimbursement by KPSC for outside care requires that claims be submitted with documentation of the care provided; claims are subsequently entered into the administrative data systems. Thus, capture of care delivered to KPSC members by electronic data is very comprehensive. Study Population The study population consisted of hospitalized KPSC members aged ≥60 years at the time of admission who had a positive RSV or influenza A/B laboratory test (multiplex polymerase chain reaction [PCR] [FilmArray, Luminex xTAG], influenza A/B/H1N1 [Cepheid Xpert Flu], or viral culture) that was ordered between 1 January 2011 and 30 June 2015 during a hospitalization encounter or an emergency department encounter that resulted in hospitalization at 1 of 15 KPSC hospitals. All samples were submitted to a single, centralized KPSC laboratory for processing. Participants were required to have continuous KPSC membership for at least 6 months (allowing a 31-day gap) prior to the hospital admission date to allow for ascertainment of baseline characteristics. If there were patients with multiple hospitalizations who met the above criteria (eg, had a positive RSV or influenza A/B test on 2 separate hospitalization encounters), the first RSV or first influenza hospitalization was kept for the RSV or influenza cohort, respectively. For the purpose of statistical comparison, independent samples of RSV and influenza cohorts were defined. Twenty-five individuals with both a positive RSV test and a positive influenza test during different hospitalizations during the study period were kept in the RSV cohort and removed from the influenza cohort. Nineteen individuals coinfected with RSV and influenza during the same hospitalization were excluded from the comparison. The KPSC Institutional Review Board reviewed and approved the study. Source of Data Electronic medical records were used to obtain information for the study population, including membership history, baseline characteristics, demographics, comorbidities, treatments, utilization, and outcomes. Each KPSC health plan member has a unique medical record number that is used as an identifier to retrieve and link all variables from different databases. Hospitalization Outcomes Outcomes of hospitalization included length of stay, occurrence of complications, use of respiratory support, intensive care unit (ICU) admission, readmission, use of vasopressors, mortality, exacerbation of chronic conditions, discharge location, and healthcare utilization after discharge. Statistical Analyses Patient demographics, prehospital course, comorbid conditions, and in-hospital utilization were compared between patients hospitalized with RSV and those hospitalized with influenza A/B using a χ2 test, Fisher exact test, t test, or Wilcoxon rank-sum test,